JP2023052258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023052258A5 JP2023052258A5 JP2023001177A JP2023001177A JP2023052258A5 JP 2023052258 A5 JP2023052258 A5 JP 2023052258A5 JP 2023001177 A JP2023001177 A JP 2023001177A JP 2023001177 A JP2023001177 A JP 2023001177A JP 2023052258 A5 JP2023052258 A5 JP 2023052258A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fusion protein
- disease
- group
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15150786 | 2015-01-12 | ||
| EP15150786.0 | 2015-01-12 | ||
| JP2020209139A JP7208963B2 (ja) | 2015-01-12 | 2020-12-17 | Ｉｌ－１７ａ結合ポリペプチド |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209139A Division JP7208963B2 (ja) | 2015-01-12 | 2020-12-17 | Ｉｌ－１７ａ結合ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023052258A JP2023052258A (ja) | 2023-04-11 |
| JP2023052258A5 true JP2023052258A5 (enExample) | 2023-07-19 |
| JP7456024B2 JP7456024B2 (ja) | 2024-03-26 |
Family
ID=52339024
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535976A Active JP6943764B2 (ja) | 2015-01-12 | 2016-01-12 | Ｉｌ−１７ａ結合ポリペプチド |
| JP2020209139A Active JP7208963B2 (ja) | 2015-01-12 | 2020-12-17 | Ｉｌ－１７ａ結合ポリペプチド |
| JP2023001177A Active JP7456024B2 (ja) | 2015-01-12 | 2023-01-06 | Ｉｌ－１７ａ結合ポリペプチド |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535976A Active JP6943764B2 (ja) | 2015-01-12 | 2016-01-12 | Ｉｌ−１７ａ結合ポリペプチド |
| JP2020209139A Active JP7208963B2 (ja) | 2015-01-12 | 2020-12-17 | Ｉｌ－１７ａ結合ポリペプチド |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10934335B2 (enExample) |
| EP (3) | EP4643955A2 (enExample) |
| JP (3) | JP6943764B2 (enExample) |
| KR (2) | KR20240110106A (enExample) |
| CN (1) | CN108064235A (enExample) |
| AU (1) | AU2016208161B2 (enExample) |
| CA (1) | CA2972683A1 (enExample) |
| DK (1) | DK3245224T3 (enExample) |
| ES (1) | ES2822431T3 (enExample) |
| HU (1) | HUE052121T2 (enExample) |
| IL (1) | IL253004B (enExample) |
| MX (1) | MX394167B (enExample) |
| MY (1) | MY188784A (enExample) |
| NZ (1) | NZ732978A (enExample) |
| PL (1) | PL3245224T3 (enExample) |
| PT (1) | PT3245224T (enExample) |
| RU (1) | RU2749712C2 (enExample) |
| WO (1) | WO2016113246A1 (enExample) |
| ZA (1) | ZA201704366B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| CN108949789A (zh) * | 2018-06-26 | 2018-12-07 | 山东兴瑞生物科技有限公司 | 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用 |
| CN120025437A (zh) * | 2019-01-31 | 2025-05-23 | 努玛治疗有限公司 | 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法 |
| US20220389066A1 (en) * | 2019-11-05 | 2022-12-08 | Affibody Ab | Polypeptides |
| CN111856029B (zh) * | 2020-06-19 | 2023-09-26 | 北华大学 | Il-17a蛋白在膀胱癌中的应用 |
| CN118632866A (zh) * | 2022-02-08 | 2024-09-10 | 阿菲博迪公司 | 结合胸腺基质淋巴细胞生成素的蛋白质z变体及其医疗用途 |
| WO2023196913A2 (en) | 2022-04-07 | 2023-10-12 | Acelyrin, Inc. | Methods of treating ankylosing spondylitis |
| EP4504235A4 (en) * | 2022-04-07 | 2025-11-19 | Acelyrin Inc | TREATMENT METHODS FOR HIDRADENITIS SUPPURATIVE |
| WO2024227930A1 (en) * | 2023-05-04 | 2024-11-07 | Affibody Ab | New polypeptide |
| CN116466095B (zh) * | 2023-06-15 | 2023-09-01 | 朗肽生物制药股份有限公司 | 一种多肽及其应用 |
| WO2025054498A1 (en) * | 2023-09-08 | 2025-03-13 | Acelyrin, Inc. | Methods of treating hidradenitis suppurativa |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| DK1963368T6 (da) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| CA2675137A1 (en) | 2007-01-12 | 2008-07-24 | Sea Lane Biotechnologies, Llc. | Combinatorial libraries of conformationally constrained polypeptide sequences |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| ES2373832T3 (es) * | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| PE20160653A1 (es) * | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| EP2544785B1 (en) * | 2010-03-08 | 2015-09-30 | GE Healthcare Bio-Sciences AB | Immunoglobulin g fc region binding polypeptide |
| CN110437321A (zh) | 2010-07-09 | 2019-11-12 | 阿菲博迪公司 | 多肽 |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| EP2597102A1 (en) * | 2011-11-25 | 2013-05-29 | Covagen AG | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 |
| WO2013126006A1 (en) * | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
| EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
| JP6590695B2 (ja) | 2012-09-25 | 2019-10-16 | アフィボディ・アーベー | アルブミン結合ポリペプチド |
| KR102151289B1 (ko) * | 2012-10-25 | 2020-09-02 | 애피바디 에이비 | Abd 결합 폴리펩티드 |
| AU2014207321A1 (en) | 2013-01-21 | 2015-07-23 | Abbvie Inc. | Anti-TNF and anti-IL17 combination therapy biomarkers for inflammatory disease |
| CA2902657C (en) * | 2013-03-15 | 2022-05-10 | Affibody Ab | Fcrn binding polypeptides |
| WO2015091957A1 (en) | 2013-12-20 | 2015-06-25 | Affibody Ab | Engineered albumin binding polypeptide |
-
2016
- 2016-01-12 KR KR1020247022438A patent/KR20240110106A/ko active Pending
- 2016-01-12 JP JP2017535976A patent/JP6943764B2/ja active Active
- 2016-01-12 KR KR1020177021726A patent/KR102683288B1/ko active Active
- 2016-01-12 DK DK16700424.1T patent/DK3245224T3/da active
- 2016-01-12 RU RU2017127012A patent/RU2749712C2/ru active
- 2016-01-12 PT PT167004241T patent/PT3245224T/pt unknown
- 2016-01-12 EP EP25184869.3A patent/EP4643955A2/en active Pending
- 2016-01-12 MX MX2017008660A patent/MX394167B/es unknown
- 2016-01-12 NZ NZ732978A patent/NZ732978A/en unknown
- 2016-01-12 EP EP16700424.1A patent/EP3245224B1/en active Active
- 2016-01-12 WO PCT/EP2016/050456 patent/WO2016113246A1/en not_active Ceased
- 2016-01-12 ES ES16700424T patent/ES2822431T3/es active Active
- 2016-01-12 AU AU2016208161A patent/AU2016208161B2/en active Active
- 2016-01-12 CA CA2972683A patent/CA2972683A1/en active Pending
- 2016-01-12 PL PL16700424T patent/PL3245224T3/pl unknown
- 2016-01-12 US US15/538,890 patent/US10934335B2/en active Active
- 2016-01-12 CN CN201680011379.3A patent/CN108064235A/zh active Pending
- 2016-01-12 EP EP20180610.6A patent/EP3738976B1/en active Active
- 2016-01-12 MY MYPI2017702236A patent/MY188784A/en unknown
- 2016-01-12 HU HUE16700424A patent/HUE052121T2/hu unknown
-
2017
- 2017-06-19 IL IL253004A patent/IL253004B/en active IP Right Grant
- 2017-06-27 ZA ZA2017/04366A patent/ZA201704366B/en unknown
-
2020
- 2020-12-17 JP JP2020209139A patent/JP7208963B2/ja active Active
-
2021
- 2021-02-01 US US17/163,961 patent/US12221464B2/en active Active
-
2023
- 2023-01-06 JP JP2023001177A patent/JP7456024B2/ja active Active
-
2024
- 2024-07-31 US US18/790,379 patent/US20250101074A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052258A5 (enExample) | ||
| US10576162B2 (en) | Bifunctional polypeptides | |
| JP2021073174A5 (enExample) | ||
| JP2023076828A5 (enExample) | ||
| IL308851B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| AU2020380296A1 (en) | IL-2RβγC binding compounds | |
| ES2199941T3 (es) | Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j. | |
| JP2006514607A5 (enExample) | ||
| JP2012530145A5 (enExample) | ||
| JP2004248677A5 (enExample) | ||
| JPWO2020063488A5 (enExample) | ||
| JP2013513377A5 (enExample) | ||
| JP2014224121A5 (enExample) | ||
| JP2019530441A5 (enExample) | ||
| JP2021501201A5 (enExample) | ||
| JP2023093634A5 (enExample) | ||
| JPWO2020053239A5 (enExample) | ||
| JPWO2021092081A5 (enExample) | ||
| Pardridge et al. | Brain capillary 46,000 dalton protein is cytoplasmic actin and is localized to endothelial plasma membrane | |
| Aoki et al. | Comparison of the amino acid and nucleotide sequences between human and two guinea pig major basic proteins | |
| JP2019518713A5 (enExample) | ||
| ES2240475T3 (es) | Peptidos terapeuticos. | |
| JP2005515981A5 (enExample) | ||
| JP2006524183A5 (enExample) | ||
| CA2581110A1 (en) | Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions |